Physician profile
Mona D Mislankar
NPI 1669714820
$7,931.11
in general payments reported to CMS, 2019-2025
32 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $822 · 2021: $1,461 · 2022: $749 · 2023: $2,190 · 2024: $1,365 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.34 |
| Education | $144.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,657.47 | 2019-2025 | |
| Janssen Biotech, INC. | $839.35 | 2019-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $713.84 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $423.19 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $392.52 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $372.31 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $367.37 | 2020-2021 | |
| Pfizer INC. | $339.26 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $296.49 | 2019-2024 | Dupixent |
| Genzyme Corporation | $270.35 | 2019-2024 | |
| Almirall LLC | $262.14 | 2019-2023 | Klisyri |
| Incyte Corporation | $251.56 | 2022-2024 | Opzelura |
| Ucb, INC. | $218.47 | 2019-2024 | Cimzia, Bimzelx |
| Leo Pharma INC. | $217.64 | 2019-2023 | Adbry |
| Galderma Laboratories, L.P. | $180.62 | 2019-2025 | Dysport |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $171.76 | 2023 | Xtrac |
| Allergan, INC. | $160.71 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $123.68 | 2019-2021 | |
| Dermavant Sciences, INC. | $108.73 | 2023-2024 | Vtama |
| Amgen INC. | $102.20 | 2021-2024 | Otezla |
| Janssen Scientific Affairs, LLC | $101.48 | 2019 | |
| Arcutis Biotherapeutics, INC. | $61.73 | 2023-2024 | Zoryve |
| Epi Health, LLC | $53.63 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $51.13 | 2019-2020 | |
| Celgene Corporation | $44.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.92 | 2021 | |
| Revance Therapeutics, INC. | $27.99 | 2024 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.69 | 2024 | Spevigo |
| Dermira, INC. | $18.45 | 2021 | |
| Mission Pharmacal Company | $16.01 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.61 | 2024 | Ycanth |
| Medimetriks Pharmaceuticals, INC. | $14.18 | 2024 | Clindacin Etz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Mislankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.